# AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
Canonical URL: https://biopharmsignal.com/news/ANTX/an2-therapeutics-reports-positive-enabling-data-supporting-advancement-of-oral-an2-502998-to-phase-2-study-for-chronic-chagas-disease
Ticker: ANTX
Company: AN2 Therapeutics
Source: AN2 Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://investor.an2therapeutics.com
## Summary

Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans Phase 1 First-In-Human (FIH) study showed favorable safety and tolerability profile; no dose-limiting toxicities

## Article Body
Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans Phase 1 First-In-Human (FIH) study showed favorable safety and tolerability profile; no dose-limiting toxicities
## Recent Company News
- 2026-06-25 13:46 EST — [AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease](https://biopharmsignal.com/news/ANTX/an2-therapeutics-reports-positive-enabling-data-supporting-advancement-of-oral-an2-502998-to-phase-2-study-for-chronic-chagas-disease) — Source: AN2 Therapeutics
- 2026-06-25 13:46 EST — [AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/ANTX/an2-therapeutics-to-present-at-2026-jefferies-global-healthcare-conference) — Source: AN2 Therapeutics
- 2026-06-25 13:46 EST — [AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights](https://biopharmsignal.com/news/ANTX/an2-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-and-scientific-highlights) — Source: AN2 Therapeutics
- 2026-06-25 13:46 EST — [AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum](https://biopharmsignal.com/news/ANTX/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum) — Source: AN2 Therapeutics
- 2026-06-25 13:46 EST — [AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights](https://biopharmsignal.com/news/ANTX/an2-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business-and-scientific-highlights) — Source: AN2 Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)